Cover Image

Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Zhimin Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song, Shui Wang, Ting Luo, Wenhe Zhao, Haibo Wang, Yueyin Pan, Jianyun Nie, Xiaohua Zeng, Yanqing Bai, Wendy Chiang, Valeria Guarnaccia, Yu Bi, Binghe Xu
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Cancer Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study
Published: (2024)

Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
by: Yun Wu, et al.
Published: (2024)

Real‐world progression‐free survival and overall survival in patients with HR + / HER2 − advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study
by: Peter A. Fasching, et al.
Published: (2026)

Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
by: Jasmine S. Sukumar, et al.
Published: (2024)

Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
by: Xu Liang, et al.
Published: (2024)

Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry
by: Marc Thill, et al.
Published: (2024)

Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016)
by: Peng Xu, et al.
Published: (2024)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024)

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study
by: Jiahui Huang, et al.
Published: (2026)

Relapsing eosinophilic pneumonia in a patient with recurrent breast cancer receiving abemaciclib plus endocrine therapy
by: Hiroaki Ogata, et al.
Published: (2024)

17‐1: Study on the Influence of Scan Time on the Test Accuracy of High PPI Fast LCD Product Response Time
by: Xinfang Li, et al.
Published: (2025)

37‐3: Study on the Influence of Scan Time on the Test Accuracy of High‐ppi Fast LCD Product Response Time
by: Xinfang Li, et al.
Published: (2025)

The evolution and prognostic impact of HER2‐low, HER2‐ultralow, and HER2‐null status in HER2‐negative early breast cancer: A pre– to post–neoadjuvant chemotherapy study
by: Yibin Qiu, et al.
Published: (2026)

Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
by: Eudald Felip, et al.
Published: (2025)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024)

Current and future patterns of vascular plant species richness across a forest–grassland–desert transect in East Asia
by: Binghe Li, et al.
Published: (2024)

Effects of aerobic exercise on neurocognitive function in postmenopausal women receiving endocrine therapy for breast cancer: The Exercise Program in Cancer and Cognition randomized controlled trial
by: Catherine M. Bender, et al.
Published: (2024)

Understanding the Role of H2O in Heterogeneous Catalysis of COx Hydrogenation
by: Zhiqiang Yan, et al.
Published: (2024)

Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
by: Hiroji Iwata, et al.
Published: (2024)

WearPPG ‐Former: A Wearable‐Optimized Transformer Using Dynamic Sparse Attention for Motion‐Resilient HR Estimation Under Intense Exercise Scenarios
by: Haibo Wang, et al.
Published: (2025)

Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
by: Peng Yuan, et al.
Published: (2024)

p95HER2 expression in HER2‐positive breast cancer with primary resistance
by: Chih Wan Goh, et al.
Published: (2024)

Quantitative Factors Introduced in the Feasibility Analysis of Reactive Oxygen Species (ROS)‐Sensitive Triggers
by: Shameer M. Kondengadan, et al.
Published: (2024)

Quantitative Factors Introduced in the Feasibility Analysis of Reactive Oxygen Species (ROS)‐Sensitive Triggers
by: Shameer M. Kondengadan, et al.
Published: (2024)

Luteinizing hormone is independently associated with high‐sensitive cardiac troponin T elevation in postmenopausal T2DM patients: A cross‐sectional study
by: Yahao Wang, et al.
Published: (2024)

Recurrent oral ulcer on a man's tongue
by: Shuangshuang Wu, et al.
Published: (2024)

R-Debater: Retrieval-Augmented Debate Generation through Argumentative Memory
by: Li, Maoyuan, et al.
Published: (2025)

Distinct Clinicopathological Features of HER2 ‐Negative, HER2 ‐Low, and HER2 ‐Overexpressing Urothelial Carcinoma in a Large Chinese Cohort
by: Shanshan Wang, et al.
Published: (2025)

Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer
by: Stephanie L. Graff, et al.
Published: (2025)

Readability-guided Idiom-aware Sentence Simplification (RISS) for Chinese
by: Zhang, Jingshen, et al.
Published: (2024)

A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer
by: Kathy D. Miller, et al.
Published: (2026)

HER2‐positive grade 1 invasive carcinomas of the breast
by: Andrew H S Lee, et al.
Published: (2024)

HER2 mutation as an emerging target in advanced breast cancer
by: Giulia Bon, et al.
Published: (2024)

Hf Addition Enhances Structural Stability and Mechanical Properties of NiTi Alloys across a Broad Temperature Range
by: Bo Li, et al.
Published: (2025)

NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer
by: Yi‐Yu Chen, et al.
Published: (2026)

SL(2,Z) modular forms and Witten genus in odd dimensions
by: Guan, Jianyun, et al.
Published: (2024)

Comprehensive Analysis of NADH:Ubiquinone Oxidoreductase Subunit B3 in Gynecological Tumors and Identification of Its Natural Inhibitor Wedelolactone
by: Huiping Li, et al.
Published: (2024)

Thermal Conductivities of Suspended Graphene/MoS 2 Van der Waals Heterostructures Measured by Raman Spectroscopy
by: Xiaohua Zhang, et al.
Published: (2025)

Prognostic implications of HER2NEU‐low in metastatic breast cancer
by: Zachary Neubauer, et al.
Published: (2024)

Clinicopathological importance of Bcl‐2 and p53 in postmenopausal triple‐negative breast carcinoma and association with age
by: Kei Ito, et al.
Published: (2024)